Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching
BackgroundClinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19). However, evidence regarding its real-world effectiveness and safety profile remains limited.ObjectiveTo evaluate the effectiveness and safety...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1584261/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849422207149670400 |
|---|---|
| author | Jing Zhang Fang Wang Ying Xie Qianyu Li Zhenzhen Zhu Yuan Dong |
| author_facet | Jing Zhang Fang Wang Ying Xie Qianyu Li Zhenzhen Zhu Yuan Dong |
| author_sort | Jing Zhang |
| collection | DOAJ |
| description | BackgroundClinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19). However, evidence regarding its real-world effectiveness and safety profile remains limited.ObjectiveTo evaluate the effectiveness and safety of azvudine in COVID-19 patients.MethodsThis retrospective cohort study included 192 COVID-19 patients hospitalized in Fengtai District, Beijing, from November 1 to December 31, 2022. Patients were divided into azvudine (n=118) and non-azvudine (n=74) groups. Propensity score matching (PSM) was applied to balance baseline characteristics (age, sex, vaccination status, etc.), yielding 48 matched pairs. Outcomes included time to SARS-CoV-2 RNA negativity, hospitalization duration, and symptom resolution (fever, cough). Adverse events were recorded.ResultsAfter PSM, 48 pairs of COVID-19 patients were identified. The azvudine group exhibited significantly shorter hospitalization than the non-azvudine group (median: 8 vs. 10 days, P ≤ 0.05). No significant differences were observed in time to RNA negativity (4.23 vs. 4.52 days, P>0.05), fever duration (2 vs. 2 days, P>0.05), or cough duration (4.5 vs. 5 days, P>0.05). One case of mild gastrointestinal discomfort was reported in the azvudine group.ConclusionAzvudine significantly reduced hospitalization duration in mild-to-moderate COVID-19 patients with a favorable safety profile. |
| format | Article |
| id | doaj-art-3c3a1a9fc17c47bd9bfffe5f9373e1e1 |
| institution | Kabale University |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-3c3a1a9fc17c47bd9bfffe5f9373e1e12025-08-20T03:31:11ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-06-011510.3389/fcimb.2025.15842611584261Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matchingJing ZhangFang WangYing XieQianyu LiZhenzhen ZhuYuan DongBackgroundClinical trials have demonstrated the efficacy of azvudine in alleviating clinical symptoms among patients with coronavirus disease 2019 (COVID-19). However, evidence regarding its real-world effectiveness and safety profile remains limited.ObjectiveTo evaluate the effectiveness and safety of azvudine in COVID-19 patients.MethodsThis retrospective cohort study included 192 COVID-19 patients hospitalized in Fengtai District, Beijing, from November 1 to December 31, 2022. Patients were divided into azvudine (n=118) and non-azvudine (n=74) groups. Propensity score matching (PSM) was applied to balance baseline characteristics (age, sex, vaccination status, etc.), yielding 48 matched pairs. Outcomes included time to SARS-CoV-2 RNA negativity, hospitalization duration, and symptom resolution (fever, cough). Adverse events were recorded.ResultsAfter PSM, 48 pairs of COVID-19 patients were identified. The azvudine group exhibited significantly shorter hospitalization than the non-azvudine group (median: 8 vs. 10 days, P ≤ 0.05). No significant differences were observed in time to RNA negativity (4.23 vs. 4.52 days, P>0.05), fever duration (2 vs. 2 days, P>0.05), or cough duration (4.5 vs. 5 days, P>0.05). One case of mild gastrointestinal discomfort was reported in the azvudine group.ConclusionAzvudine significantly reduced hospitalization duration in mild-to-moderate COVID-19 patients with a favorable safety profile.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1584261/fullazvudineCOVID-19propensity score matchinghospitalization durationretrospective study |
| spellingShingle | Jing Zhang Fang Wang Ying Xie Qianyu Li Zhenzhen Zhu Yuan Dong Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching Frontiers in Cellular and Infection Microbiology azvudine COVID-19 propensity score matching hospitalization duration retrospective study |
| title | Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching |
| title_full | Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching |
| title_fullStr | Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching |
| title_full_unstemmed | Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching |
| title_short | Effectiveness and safety of azvudine in the treatment of COVID-19 patients: a retrospective cohort study using propensity score matching |
| title_sort | effectiveness and safety of azvudine in the treatment of covid 19 patients a retrospective cohort study using propensity score matching |
| topic | azvudine COVID-19 propensity score matching hospitalization duration retrospective study |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1584261/full |
| work_keys_str_mv | AT jingzhang effectivenessandsafetyofazvudineinthetreatmentofcovid19patientsaretrospectivecohortstudyusingpropensityscorematching AT fangwang effectivenessandsafetyofazvudineinthetreatmentofcovid19patientsaretrospectivecohortstudyusingpropensityscorematching AT yingxie effectivenessandsafetyofazvudineinthetreatmentofcovid19patientsaretrospectivecohortstudyusingpropensityscorematching AT qianyuli effectivenessandsafetyofazvudineinthetreatmentofcovid19patientsaretrospectivecohortstudyusingpropensityscorematching AT zhenzhenzhu effectivenessandsafetyofazvudineinthetreatmentofcovid19patientsaretrospectivecohortstudyusingpropensityscorematching AT yuandong effectivenessandsafetyofazvudineinthetreatmentofcovid19patientsaretrospectivecohortstudyusingpropensityscorematching |